Enter your email address:Delivered by FeedBurner Subscribe to this blog's feed Bayer CropScience AG v. Dow Agrosciences LLC (Fed. Conference & CLE Calendar Washington College of Law Post-Argument Discussion of Impression Products v. Lexmark International Webinar on Latest PTAB Decisions Webcast on Patent Infringement Damages PTAB Life Sciences Report -- Part III Judge Bryson Rules That Jury Need Not Be Apprised of Presumption of Validity Standard for Granted Claims PTAB Life Sciences Report -- Part II Intellectual Ventures LLC v. Semantic Corporation and Veritas Technologies LLC (D. Del. 2017)to the king Be it unto the king, be it to the kingEzra 4:13 HEB: כְּעַ֗ן יְדִ֙יעַ֙ לֶהֱוֵ֣א לְמַלְכָּ֔אNAS: Now let it be known to the king,KJV: Be it known now unto the king,INT: Now it be known become to the kingEzra 4:14 HEB: דְּנָ֔ה שְׁלַ֖חְנָא וְהוֹדַ֥עְנָא לְמַלְכָּֽא׃ NAS: we have sent and informed the king,KJV: have we sent and certified the king;INT
: time have sent and informed the kingEzra 4:15 HEB: בִּסְפַ֣ר דָּכְרָנַיָּא֮ וְתִנְדַּע֒ דִּי֩ קִרְיְתָ֨אNAS: books and learn that that cityKJV: of the records, and know that thisINT: books the record and learn so cityEzra 4:16 HEB: מְהוֹדְעִ֤ין אֲנַ֙חְנָה֙ לְמַלְכָּ֔אNAS: We inform the king that ifKJV: We certify the king that, ifINT: inform We the kingEzra 5:8 HEB: יְדִ֣יעַ ׀ לֶהֱוֵ֣א לְמַלְכָּ֗אNAS: Let it be known to the kingINT: it be known become to the kingEzra 5:10 HEB: שְׁאֵ֥לְנָא לְּהֹ֖ם לְהוֹדָעוּתָ֑ךְ דִּ֛י נִכְתֻּ֥בNAS: them their names so as to inform you, and that we might write downKJV: also, to certify thee, that we might writeINT: their names asked to inform who writeEzra 7:24 HEB: וּלְכֹ֣ם מְהוֹדְעִ֗ין דִּ֣י כָל־NAS: We also inform you that it is not allowedKJV: Also we certify you, that touching anyINT: inform forasmuch anyEzra 7:25 HEB: נַהֲרָ֔ה לְכָל־ יָדְעֵ֖י דָּתֵ֣י אֱלָהָ֑ךְNAS: [even] all those who know the lawsKJV: all such as know the lawsINT: the River all know the laws of your GodEzra 7:25 HEB: וְדִ֧י לָ֦א יָדַ֖ע תְּהוֹדְעֽוּן׃ NAS: of your God;
and you may teach anyone whoKJV: of thy God; and teach ye them that knowINT: who not may teach knowEzra 7:25 HEB: לָ֦א יָדַ֖ע תְּהוֹדְעֽוּן׃ KJV: and teach ye them that know [them] not.INT: not may teach knowDaniel 2:5 HEB: הֵ֣ן לָ֤א תְהֽוֹדְעוּנַּ֙נִי֙ חֶלְמָ֣א וּפִשְׁרֵ֔הּNAS: if you do not make known to me the dreamKJV: ye will not make known unto me the dream,INT: if will not make the dream interpretationDaniel 2:8 HEB: מִן־ יַצִּיב֙ יָדַ֣ע אֲנָ֔ה דִּ֥יNAS: replied, I know for certainKJV: and said, I know of certaintyINT: of certain know I forDaniel 2:9 HEB: חֶלְמָא֩ לָ֨א תְהֽוֹדְעֻנַּ֜נִי חֲדָה־ הִ֣יאNAS: that if you do not make the dreamKJV: ye will not make known unto me the dream,INT: the dream will not make one itDaniel 2:9 HEB: אֱמַ֣רוּ לִ֔י וְֽאִנְדַּ֕ע דִּ֥י פִשְׁרֵ֖הּNAS: the dream known to me, there is only oneKJV: me the dream, and I shall know thatINT: the dream tell known its interpretationDaniel 2:15 HEB: אֱדַ֣יִן מִלְּתָ֔א הוֹדַ֥ע אַרְי֖וֹךְ לְדָנִיֵּֽאל׃NAS: Arioch informed DanielKJV: Arioch made the thing known to Daniel.INT: Then the matter informed Arioch DanielDaniel 2:17 HEB: חַבְר֖וֹהִי מִלְּתָ֥א הוֹדַֽע׃ NAS: to his house and informed his friends,KJV: and made the thing known to Hananiah
,INT: his friends the matter and informedDaniel 2:21 HEB: לְחַכִּימִ֔ין וּמַנְדְּעָ֖א לְיָדְעֵ֥י בִינָֽה׃ KJV: and knowledge to them that know understanding:INT: to wise and knowledge know of understandingDaniel 2:22 HEB: עַמִּיקָתָ֖א וּמְסַתְּרָתָ֑א יָדַע֙ מָ֣ה בַחֲשׁוֹכָ֔אNAS: and hidden things; He knows whatKJV: and secret things: he knoweth whatINT: the profound and hidden knows what the darknessDaniel 2:23 HEB: לִ֑י וּכְעַ֤ן הֽוֹדַעְתַּ֙נִי֙ דִּֽי־ בְעֵ֣ינָאNAS: Even now You have made knownKJV: and might, and hast made known unto me nowINT: have given now have made what requestedDaniel 2:23 HEB: מִלַּ֥ת מַלְכָּ֖א הוֹדַעְתֶּֽנָא׃ NAS: You have made known to me whatKJV: of thee: for thou hast [now] made known unto us the king'sINT: matter the king's knownDaniel 2:25 HEB: פִשְׁרָ֖א לְמַלְכָּ֥א יְהוֹדַֽע׃ NAS: who can make the interpretationKJV: Judah, that will make known unto the kingINT: the interpretation to the king makeDaniel 2:26 HEB: ק) כָּהֵ֗ל לְהוֹדָעֻתַ֛נִי חֶלְמָ֥א דִֽי־NAS: Are you able to make known to me the dreamKJV: thou able to make known unto me the dreamINT
: art thou able to make the dream whichDaniel 2:28 HEB: גָּלֵ֣א רָזִ֔ין וְהוֹדַ֗ע לְמַלְכָּא֙ נְבֽוּכַדְנֶצַּ֔רNAS: mysteries, and He has made known to KingKJV: secrets, and maketh known to the kingINT: reveals mysteries has made to King NebuchadnezzarDaniel 2:29 HEB: וְגָלֵ֧א רָזַיָּ֛א הוֹדְעָ֖ךְ מָה־ דִ֥יNAS: mysteries has made known to you whatKJV: secrets maketh known to thee whatINT: reveals mysteries has made what forasmuchOpen Tue through Sun 10am - 5pm, Closed Mondays | WIN A TRIP TO ENGLANDHERTFORDSHIRE, England and PITTSBURGH, Jan. 30, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the United States District Court for the District of Delaware issued a decision finding all asserted claims of four Orange Book-listed patents relating to Copaxone® 40 mg/mL invalid based on obviousness. The invalidated patents are United States Patent Numbers 8,232,250; and 9,155,776, which are owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries, Ltd.
On Dec. 2, 2016, the U.S. Patent and Trademark Office's U.S. Patent Trial and Appeal Board (PTAB) reaffirmed a prior decision that three of these patents ('250, '413 and '302) are unpatentable in its inter partes review (IPR) proceedings initiated by Mylan. Mylan also challenged the '776 patent in an IPR proceeding. The PTAB is expected to issue its institution ruling on the '776 patent IPR by May 16, 2017. Mylan CEO Heather Bresch commented, "Today's ruling by the U.S. District Court is yet another positive step in our effort to bring to market a more affordable generic version of Copaxone® 40 mg/mL. We will continue to challenge the validity of patents as a way to expedite the availability of generic drugs and help deliver access and savings to patients and the overall healthcare system." Mylan believes it is one of the first companies to have filed a substantially complete abbreviated new drug application containing a Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/mL
Copaxone 40 mg/mL had U.S. sales of approximately $3.3 billion for the 12 months ending Nov. 30, 2016, according to IMS Health. This press release includes statements that constitute "forward-looking statements," including that Mylan will continue to challenge the validity of patents as a way to expedite the availability of generic drugs and help deliver access and savings to patients and the overall healthcare system; that the PTAB is expected to issue its institution ruling on the '776 patent IPR by ; and that Mylan believes it is one of the first companies to have filed a substantially complete abbreviated new drug application containing a Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/mL. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent our introduction of new products; actions taken by regulatory and governmental agencies with respect to our or our competitors' current or future products; success of clinical trials and our ability to execute on new product opportunities; other risks inherent in legal and regulatory processes, uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release. Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs;